<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03904550</url>
  </required_header>
  <id_info>
    <org_study_id>STU-2018-0411</org_study_id>
    <nct_id>NCT03904550</nct_id>
  </id_info>
  <brief_title>Neuromuscular Blockade in Patients With Severe Renal Impairment</brief_title>
  <official_title>Reversal of Neuromuscular Blockade in Patients With Severe Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to be a single-site, prospective, randomized, double-blinded study&#xD;
      that intends to enroll a total of 60 patients with severe renal impairment undergoing surgery&#xD;
      with general endotracheal anesthesia at Parkland Hospital. Patients will be randomized to&#xD;
      receive either neostigmine (for reversal of cisatracurium) or sugammadex (for reversal of&#xD;
      rocuronium). A standardized anesthetic protocol that is usual and customary for the type of&#xD;
      operation the patient is having will be provided to the anesthesia teams of enrolled&#xD;
      subjects. The remainder of the anesthetic care of the subject will not deviate from the&#xD;
      standard of care. All patients will be monitored with continuous pulse oximetry&#xD;
      postoperatively for 24 hours.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective, randomized, double-blinded study of surgical patients with severe&#xD;
      renal impairment that seeks to address the following:&#xD;
&#xD;
      Specific Aim:&#xD;
&#xD;
      To determine whether rocuronium-induced moderate neuromuscular blockade and reversal with&#xD;
      sugammadex achieves recovery of neuromuscular function (TOF ≥ 0.9) faster than reversal of&#xD;
      cisatracurium-induced moderate neuromuscular blockade and reversal with neostigmine in&#xD;
      patients with severe renal impairment.&#xD;
&#xD;
      Primary Hypothesis:&#xD;
&#xD;
      Patients with severe renal impairment who are reversed with sugammadex after rocuronium will&#xD;
      achieve a TOF ≥0.9 within a time frame that is one-third of the time it takes for reversal&#xD;
      with neostigmine after cisatracurium.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>single site, randomized, controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time until complete reversal of neuromuscular blockade</measure>
    <time_frame>In the operating room from induction to extubation.</time_frame>
    <description>Measure how long it takes to return from a TOF of 2 to a TOF ≥ 0.9.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Cisatracurium + Neostigmine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the rocuronium/sugammadex group will receive 0.6 mg/kg of rocuronium for neuromuscular paralysis during induction. Additional rocuronium will be given to keep the patient at a neuromuscular depth of 1 twitch throughout the surgery until the last 30 minutes, during which the patient will be kept at 2 twitches.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rocuronium + Sugammadex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the cisatracurium/neostigmine group will receive 0.2 mg/kg of cisatracurium for neuromuscular paralysis during induction. Additional cisatracurium will be given to keep the patient at a neuromuscular depth of 1 twitch throughout the surgery until the last 30 minutes, during which the patient will be kept at 2 twitches.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisatracurium + Neostigmine</intervention_name>
    <description>Maintenance neuromuscular blockade with boluses of cisatracurium to keep train-of-four (TOF) 1-2 twitches. For reversal, neostigmine with glycopyrrolate</description>
    <arm_group_label>Cisatracurium + Neostigmine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium + Sugammadex</intervention_name>
    <description>Maintenance neuromuscular blockade with boluses of rocuronium to keep TOF 1-2 twitches. For reversal, sugammadex</description>
    <arm_group_label>Rocuronium + Sugammadex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-80 years old&#xD;
&#xD;
          -  Severe renal impairment (CrCl &lt; 30 mL/min)&#xD;
&#xD;
          -  Undergoing non-emergent surgery that requires neuromuscular blockade&#xD;
&#xD;
          -  Planned extubation in the operating room immediately after surgery&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) physical status classification 3 to 4&#xD;
&#xD;
          -  Willing and able to consent in English or Spanish&#xD;
&#xD;
          -  No personal history of neuromuscular disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 18 or older than 80&#xD;
&#xD;
          -  Patient does not speak English or Spanish&#xD;
&#xD;
          -  Planned postoperative intubation/ventilation&#xD;
&#xD;
          -  Allergy to sugammadex, neostigmine, glycopyrrolate, cisatracurium, or rocuronium&#xD;
&#xD;
          -  Family or personal history of malignant hyperthermia&#xD;
&#xD;
          -  Patient refusal&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  &quot;Stat&quot; (emergent) cases&#xD;
&#xD;
          -  Pre-existing muscle weakness of any etiology&#xD;
&#xD;
          -  Patients on toremifene (a selective estrogen receptor modulator)&#xD;
&#xD;
          -  Women on oral contraceptives who do not wish to use a non-hormonal method of&#xD;
             contraception for 7 days following surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tiffany Moon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tiffany Moon, MD</last_name>
    <phone>469-419-5790</phone>
    <email>tiffany.moon@utsouthwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthew Oh, BS</last_name>
    <phone>310-612-7741</phone>
    <email>matthew.oh@utsouthwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Parkland Health &amp; Hospital System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Moon, MD</last_name>
      <phone>469-419-5790</phone>
      <email>Tiffany.Moon@UTSouthwestern.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>April 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Tiffany B Moon</investigator_full_name>
    <investigator_title>ASSOC PROFESSOR</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Cisatracurium</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

